NCT00619788已完成2 期
Prospective, Multicenter, Non-randomized Clinical Trial Investigating the Safety and Efficacy of the AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for the Treatment of Femoropopliteal Stenotic Disease.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 6
- 主要终点
- Complication Free Survival at 1 month post-procedure (complications = major amputations defined as amputations at or above the ankle, any cause of death and TLR)
研究概览
简要总结
This investigation is designed to demonstrate the efficacy and safety of the 4.0-5.0mm AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for femoropopliteal use in a controlled clinical investigation.
The scoring balloon is a semi-compliant balloon encircled by 3 spiral struts with a nitinol scoring element, which theoretically provides targeted scoring of lesions, by concentrating the dilation force thus minimizing barotrauma, elastic recoil and uncontrolled dissection. This may improve the outcome of the intervention and reduce the number of stents required.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stenotic (>50%) or occlusive atherosclerotic disease of the femoropopliteal arteries (primarily superficial femoral arteries - SFA)
- •Length of lesion >5 cm or 2 times the AngioSculpt balloon length (whichever is longer)
- •Reference vessel diameter should be 4.0-6.0 mm
- •Life altering claudication or critical limb ischemia (Rutherford 3-5)
- •No untreated inflow-limiting arterial lesions
- •At least single vessel run-off until the ankle
- •The patient must be > 18 years.
- •Life-expectancy of more than 12 months
- •The subject or legal guardian has been informed of the nature of the evaluation; agrees to its provisions and has signed informed consent
- •The patient is capable to follow all evaluation requirements.
排除标准
- •Patient refusing treatment
- •The reference segment diameter is not suitable for available catheter design
- •Length of lesion is ≥5 cm or requires more than two overlapping AngioSculpt balloon inflations (whichever is longer) to cover the entire lesion (however, more than two inflations are permitted within an acceptable lesion length)
- •The patient has a known allergy to heparin, aspirin or other anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies
- •The patient has a history of prior life-threatening contrast media reaction
- •The patient is currently enrolled in another investigational device or drug trial
- •The patient is currently breast-feeding, pregnant or intends to become pregnant
结局指标
主要结局
Complication Free Survival at 1 month post-procedure (complications = major amputations defined as amputations at or above the ankle, any cause of death and TLR)
时间窗: 1 month
次要结局
- patency of the target lesion. Primary patency is defined as the absence of: a) target lesion revascularization (TLR); b) major amputation due to lesion restenosis or occlusion; c) conversion to bypass surgery and d) untreated significant stenosis on CFDU(12 months)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
AngioSculpt® Coronary Bifurcation StudyCoronary Artery DiseaseMyocardial IschemiaNCT00686647AngioScore, Inc.93
已完成
不适用
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal ArteriesPeripheral Artery DiseaseNCT02522884Philips Clinical & Medical Affairs Global213
已完成
3 期
Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore ThroatSore ThroatNCT03095508Sandoz229
已完成
不适用
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee ArteriesPeripheral Arterial DiseaseNCT02942966Philips Clinical & Medical Affairs Global233
Unknown
不适用
Scoring-Balloon Angioplasty and Sirolimus-Eluting Balloon Angioplasty for the Treatment of Diffuse, Small Vessel Coronary Artery Disease (SCA-DEB Study)Coronary Artery DiseaseNCT06197022University National Heart Hospital106